CAN Cann Group Limited
Healthcare · Drug Manufacturers - Specialty & Generic
· website
$0.00
52wk 0.00 – 0.02
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Cann Group Limited
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$4.98M
P/E (trailing)
0.30
P/E (forward)
0.01
EPS (trailing)
0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.05
EV / EBITDA
-2.48
Price / Book
0.14
ROE
72.6%
Operating margin
-132.8%
Net margin
130.3%
Total cash
$955,000
Total debt
$14.96M
Current ratio
0.42
Debt / Equity
0.44
Free cash flow
$-2.16M
Avg volume
5.31M
Latest annual results
(FY ending 30 Jun 2024)
- Revenue$15.37M
- Gross profit$15.37M
- Operating income-$27.50M
- Net income-$51.24M
- Diluted EPS-0.11
- Free cash flow-$17.69M
- Net debt$70.83M